Cambridge Cognition Holdings plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cambridge Cognition Holdings plc
Kiri Granger, Monument Therapeutics’ chief scientific officer and executive director, and one of In Vivo’s 2022 Rising Leaders, hopes to take the company to the next level by rejecting the conventional one-size-fits-all approach to psychiatric clinical trials.
Emerging Company Profile: Monument Therapeutics’ novel approach to CNS drug development focuses on repurposing existing drugs with the aid of digital biomarkers.
- Digital Health
- Other Names / Subsidiaries
- Cambridge Cognition Ltd
- Cambridge Cognition Holdings Ltd
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.